NEWS
Go back
ARCHIMED acquires FIM Medical, a leader in the vision, audio & respiratory medical devices market
October
15,
2024
Global private equity healthcare specialist ARCHIMED announces the acquisition of FIM Medical, the leader in the occupational health medical device market in France, with a strong international footprint. With the acquisition of FIM Medical, ARCHIMED initiates the deployment of its MED Rise fund.
Based in Lyon (France), Europe’s premier health hub and ARCHIMED’s European headquarters, FIM Medical boasts a diversified and cutting-edge range of products in the fields of vision, hearing, and respiratory care, leveraging proprietary technology in both its medical devices and software.
FIM Medical is the leader in the national French occupational health market across its primary product lines – vision testers, audiometers, and spirometers – and has successfully expanded across Europe and into the US. With a robust brand reputation and competitive edge, FIM Medical is a growing company poised for international expansion, both organically and through acquisitions.
In addition, amid a rising trend in the occupational health sector to prioritize preventative measures like regular checkups for early identification of potential health risks, FIM Medical stands out as a key contributor to improving patient outcomes through its position as a leading devices provider.
FIM Medical was sourced directly by ARCHIMED’s MedTech team, through its neuro & sensory focus which already led to investments in companies such as Micromed, Natus Neuro, Natus Sensory or Ad-Tech. MedTech is a primary investment sector for ARCHIMED and part of the eight major sectors mapped through ARCHIMED’s “MedSeg”, its proprietary sector analysis tool covering over 430 sub-segments of the global healthcare industry. The MedTech sector team’s ability to establish a close relationship with the founding family and to showcase ARCHIMED‘s “MedValue” distinctive value creation approach, led to smooth and rapid deal execution.
“ARCHIMED’s experience in MedTech and in the neuro & sensory sectors were key advantages in our decision to partner, together with their business builder’s mindset. We are confident that they are fully equipped to support our growth and drive our future expansion,” says FIM Medical CEO, Marie-Ange Derei.
“FIM Medical is a valuable addition to the ARCHIMED portfolio, strengthening our presence into the neuro, sensory and occupational health sectors, which we already know well through our investments in Vita Health, Natus Sensory, Ad-Tech and some others.”
ARCHIMED partner, Antoine Faguer
ARCHIMED has acquired FIM Medical through its MED Rise fund, which closed last April, reaching its hard cap of €400 million and a threefold oversubscription. MED Rise is ARCHIMED’s small-cap fund dedicated to buyouts within the global healthcare industries. MED Rise broadens ARCHIMED’s investment spectrum and allows the firm to invest from €10 million to €1 billion in its targeted sectors.
In terms of returns, ARCHIMED is ranked as the world’s 6th best performing Buyout firm in the latest Dow Jones-HEC ranking (out of 632 Buyout firms globally). ARCHIMED’s performance is particularly strong with regard to cash-to-cash returns, with a constant flow of liquidity events and distributions since inception, including in the last two years when most players struggled to provide liquidity.